IMMY News Alert Imprimis Pharmaceuticals Inc (IMMY) 7.77 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Imprimis Pharmaceuticals Inc (IMMY) 7.77 $IMMY

Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations to Four Key Western States
PR Newswire - Wed Dec 03, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, is expanding the availability of its Dropless formulations to over 3,000 ophthalmologists in four key states: California, Nevada, Oregon, and Hawaii. These states represent over 290 ambulatory surgery centers (ASCs) where cataract and other ocular surgeries are performed, including California which has the most ASCs dedicated to ocular surgery in the country.
IMMY: 7.77 (+0.03)

Imprimis acquires second pharmacy
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 8:43AM CST

IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Signs Agreement to Acquire PCAB-Accredited Pharmacy in California
PR Newswire - Tue Dec 02, 7:05AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced that it has entered into a stock purchase agreement to acquire South Coast Specialty Compounding, Inc., DBA Park Compounding (Park). The acquisition of Park is expected to close on or about January 1, 2015, subject to the satisfaction of certain customary closing conditions. As part of the transaction, Imprimis also entered into a non-exclusive license agreement with Park. The license agreement allows Park to immediately begin making and dispensing Imprimis' proprietary ophthalmology and urology formulations in the 13 states in which it is currently licensed, including California, Nevada, Oregon, and Hawaii.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:28PM CST

IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals EPS of -$0.27
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:26PM CST

IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Reports on Third Quarter 2014 Financial Results and Provides Update on Business Developments
PR Newswire - Wed Nov 12, 3:00PM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced financial results for the third quarter ended September 30, 2014, and provided an update on recent business developments.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals to Host its Third Quarter 2014 Financial Report Conference Call and Webcast on November 12, 2014
PR Newswire - Thu Nov 06, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, reported that it will release its third quarter 2014 financial results on Wednesday, November 12, 2014. The company will host a conference call at 1:30 p.m. PST (4:30 p.m. EST) on the same day to discuss the third quarter 2014 financial results and recent business development activities. The conference call and webcast will be open to all listeners and a question and answer session will follow the prepared remarks.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless(TM) Proprietary Formulations to Ophthalmologists in Puerto Rico
PR Newswire - Tue Nov 04, 7:00AM CST
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today announced that it has entered into a distribution agreement with MD Distributor, Corp. (MDD). Under the agreement, MDD has the rights to market, sell and distribute Imprimis' patent-pending Go Dropless(TM) formulations and other ophthalmic formulations in Puerto Rico. In addition, the agreement also covers the Dominican Republic and countries in the Caribbean once regulatory approvals are obtained. MDD represents leading healthcare companies and its experienced sales and marketing professionals are primarily focused in the specialty areas of ophthalmology and dermatology.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Enters into License Agreement for Patented Urology Formulation
PR Newswire - Wed Oct 29, 7:31AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) today announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Compounded alkalized lidocaine and heparin instillation procedures have been reimbursable by private healthcare providers and to Medicare beneficiaries under CPT Code 51700.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting
PR Newswire - Fri Oct 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American Academy of Ophthalmology (AAO) annual meeting held in Chicago, Illinois. The company also announced Dropless media coverage from AAO meeting, where it introduced a new white paper, titled, "Making Dropless Cataract Surgery Possible".
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals' Dropless Formulations to be Presented in Multiple Sessions at the 2014 American Academy of Ophthalmology (AAO) Meeting
PR Newswire - Thu Oct 16, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of high quality and innovative sterile and topical compounded drug formulations, today announces its attendance, and related "Go Dropless!(TM)" events, at the 2014 American Academy of Ophthalmology (AAO) annual meeting in Chicago, Illinois, October 17-21.
IMMY: 7.77 (+0.03)

Nasdaq stocks posting largest percentage decreases
AP - Thu Sep 25, 12:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
LOXO: 13.50 (+0.06), PSBH: 7.67 (+0.13), EGLT: 5.97 (+0.21), ICEL: 5.74 (-0.18), MSON: 11.76 (+0.14), ATTU: 10.38 (-0.07), HGSH: 4.60 (-0.06), LPCN: 5.15 (+0.01), TKMR: 13.97 (+0.14), DXM: 9.06 (+0.12), IMMY: 7.77 (+0.03), TKM.TO: 16.42 (+0.22)

Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference
PR Newswire - Tue Sep 16, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced that Chief Executive Officer Mark Baum will be a presenter at the 5th Annual Craig-Hallum Alpha Select Conference in New York City. Mr. Baum will discuss the company's growth strategy, including its Go Dropless(TM) campaign in ophthalmology. The presentation is scheduled for 10:40 a.m. EST on Thursday, September 18, 2014 at the Convene Conference Center in New York. An audio portion of this presentation will be broadcast in a live webcast, and an archive of the webcast will be available for 90 days following the event. The webcast and slides for the presentation will be available at http://wsw.com/webcast/ch4/immy/ or on the Investor Relations section of the Imprimis' website at www.imprimispharma.com.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Appoints Healthcare Leader William H. Nelson to its Board of Directors
PR Newswire - Mon Sep 08, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced the appointment of William H. Nelson to its Board of Directors, effective September 4, 2014.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
PR Newswire - Wed Aug 13, 3:30PM CDT
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients pursuant to prescriptions for individually identified patients at accessible prices, today announced selected financial results for the quarter ended June 30, 2014, and provided an update on recent operations.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals' Go Dropless(TM) Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium
PR Newswire - Thu Jul 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today that two Key Opinion Leader (KOL) presentations that describe the benefits of dropless cataract surgery formulations will be delivered at the upcoming American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium in Deer Valley, Utah from July 24 - 27, 2014.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Go Dropless(TM) Video Interview Survey Reveals 95% of Leading Cataract Surgeons Surveyed Would Prefer Dropless Therapy
PR Newswire - Tue Jun 24, 7:00AM CDT
Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, today unveiled the results of a recent survey1 of leading national cataract surgeons (www.GoDropless.com/why-go-dropless).
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
PR Newswire - Tue Mar 04, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.
IMMY: 7.77 (+0.03)

Imprimis Pharmaceuticals Names Pharmacy Business Leader Randle House as Vice President of Pharmacy Operations
PR Newswire - Wed Feb 19, 5:00AM CST
Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations, today announced that Randle House has joined the company as Vice President of Pharmacy Operations. In this role, House will head the Company's distribution and operations team to make and distribute its patent-pending proprietary drug formulations and other novel pharmaceutical solutions.
MCRS: 67.99 (unch), IHG: 40.95 (+0.29), IMMY: 7.77 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading